WO2019236521A1 - Procédés et formulations pour une administration intranasale - Google Patents

Procédés et formulations pour une administration intranasale Download PDF

Info

Publication number
WO2019236521A1
WO2019236521A1 PCT/US2019/035302 US2019035302W WO2019236521A1 WO 2019236521 A1 WO2019236521 A1 WO 2019236521A1 US 2019035302 W US2019035302 W US 2019035302W WO 2019236521 A1 WO2019236521 A1 WO 2019236521A1
Authority
WO
WIPO (PCT)
Prior art keywords
dihydroxy
dihydro
benzopyran
disorder
trihydroxybenzoate
Prior art date
Application number
PCT/US2019/035302
Other languages
English (en)
Inventor
Gian Luca Araldi
Original Assignee
Avanti Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avanti Biosciences, Inc. filed Critical Avanti Biosciences, Inc.
Publication of WO2019236521A1 publication Critical patent/WO2019236521A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Definitions

  • catechins Despite the potential beneficial effects of polyphenol derivatives, such as catechins, there are many bioavailability problems associated with the oral delivery of catechins especially into the brain. Catechins do not easily penetrate tire human digestive tract and are subject to intestine-based metabolism and rejection, and thus very ' limited amounts of orally administered catechins enter the plasma. Furthermore, the small amount of catechin that enters the bloodstream is rapidly metabolized by the liver and in plasma. Therefore, only very small amounts of orally administered catechins enter the blood and in the brain tissue.
  • the disclosure provides intranasal pharmaceutical formulations comprising a polyphenoiic compound and a pharmaceutically acceptable diluent or carrier.
  • the polyphenoiic compound comprises a compound selected from the group consisting of flavonoids, curcumin, resveratrol, or pharmaceutically acceptable salts thereof in another embodiment, the phenolic derivative comprises a catechin or a pharmaceutically acceptable salt thereof.
  • the catechin comprises one or more of (2S,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-l- benzopyran-3-yl 3,4,5-trihydroxybenzoate [i.e.
  • (+)GCG (2S,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,4-dihydro-2H-l -benzopyran-3- yl 3,4,5-trihydroxybenzoate [i.e. (-)CGj, (2R,3S)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy- 3,4-dihydro-2H- l-benzopyran-3-yl 3,4,5-trihydroxybenzoate [i.e.
  • (+)CG (2R,3R)-2-(3,4- dihydroxyphenyl)-5,7-dihydroxy-3,4-dihydro-2H- 1 -benzopyran-3 -yl 3,4,5- trihydroxybenzoate [i .e. (-)-ECG], (2S,3S)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,4- dihydro-2H- l-benzopyran-3-yl 3,4,5-trihydroxybenzoate [i .e.
  • (+)-ECG (2R,3R)5,7- dihydroxy-2-(3 ,4,5-trihydroxyphenyl)-3, 4-dihydro- 2H-l-benzopyran-3-yl 3,4,5- Trihydroxybenzoate [i .e. (-)EGCG], (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4- dihydro-2H-l-benzopyran-3-yl 3,4-dihydroxy-5- methoxybenzoate [i.e.
  • die catechin is present in the formulation at between about 1% to about 40% w/w, between about 1% to about 30% w/w, between about 1% to about 25% w/w, between about 4% to about 30% w/w, between about 5% to about 30% w/w, between about 6% to about 30% w/w, between about 8% to about 30% w/w, between about 10% to about 25% w/w, between about 1 1% to about 25% w/w, or about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%,
  • the formulation may further comprise one or more of:
  • die formulation has a pH of between 4.0 and 6.5
  • the permeation enhancer is present at 1.0% to about 20%, 1- 18%, 2-18%, 3-17%, 4-16%, 5-15%, 6-14%, 7-13%, 8-12%, 9-11%, 2.3-10%, 0.1% to 2% or about 10% w/w %.
  • the permeation enhancer comprises one or more compounds selected from the group consisting of cyclodextrin or analogs thereof, glycerin, PEG 400, sucrose monolaurate, chitosan, transmucosal delivery enhancement agents including but not limited to alkylsaccharide transmucosal deliver ⁇ ' enhancement agents (including but not limited to tetradecyl maltoside (TDM)), or pharmaceutically acceptable salts diereof.
  • TDM tetradecyl maltoside
  • the permeation enhancer comprises (2 ⁇ HydiOxypropyi) ⁇ fl- cyclodextrin (HR-b-cyclodextrin); also referred to as HR-b-CD, or Hydroxypropyl betadex), randomly methylated cyclodextrin (also referred to as IIM-b- €E>), sulfobutylether-b- cyciodextrin (also referred to as 8BE-b- €E>), sucrose monolaurate, pharmaceutically acceptable salts thereof, or combinations thereof.
  • HR-b-cyclodextrin also referred to as HR-b-CD, or Hydroxypropyl betadex
  • randomly methylated cyclodextrin also referred to as IIM-b- €E>
  • sulfobutylether-b- cyciodextrin also referred to as 8BE-b- €E>
  • sucrose monolaurate pharmaceutically acceptable salts thereof
  • the anti-oxidant/chelators is present at 0.05-15%, 0.8-15%, 0.1-15%, 0.1-10%, 0.1-9%, 0.1-6%, or about 0.2%, 1%. 2%, 3%, 4%, 5% w/w%.
  • the anti -oxidant comprises one or more compounds selected from the group consisting of ascorbic acid, sodium metabisulfite, sodium bisulfite, tocopherol, or pharmaceutically acceptable salts thereof.
  • the anti-oxidant comprises ascorbic acid or a pharmaceutically acceptable salt thereof.
  • the humectant is present at 1-25%, 1-20%, 1-15%, 1-10%, 1- 9%, 2-8%, 3-7%, 4-6%, or about 5% w/w%.
  • the humectant comprises a compound selected from the group consisting of glycerin, PEG (including but not limited to PEG 300, PEG400, and PEG 600), or a pharmaceutically acceptable salt thereof.
  • the formulation comprises a pH modifier present at 0.1-2%, 0.5-1.5% or about 1% w/w%.
  • the pH modifier comprises a compound selected from the group consisting of sodium hydroxide or a pharmaceutically acceptable salt thereof.
  • the formulation comprises a liquid, a powder, a spray, a nose drop, a gel, an ointment, or a combination thereof.
  • tire disclosure provides methods for treating a central nervous system disorder, a congenital hyperimsulinemia (CHI) disorder, a tumor, diabetes, obesity, or a systemic disorder, comprising administering to a subject in need thereof an amount effective of the intranasal pharmaceutical formulation of any embodiment or combination of embodiments of the disclosure to treat the disorder in the subject.
  • CHI congenital hyperimsulinemia
  • the disclosure provides methods for treating a central nervous system disorder, a congenital hyperinsulinemia (CHI) disorder, a tumor, diabetes, obesity, or a systemic disorder, comprising intranasal administration to a subject need thereof of an amount effective of a catechin or a pharmaceutically acceptable salt thereof to treat the disorder in the subject.
  • the catechin comprises one or more of (2S,3R)- 5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-!-benzopyran-3-yi 3 ,4,5- trihydroxy benzoate [i.e.
  • (+)GCG (2S,3R)-2-(3,4- dihydroxyphenyi) ⁇ 5 ,7 ⁇ dihydroxy-3 ,4-dihydro-2H ⁇ 1 -benzopyran -3 -yl 3,4,5- trihydroxybenzoate [i .e, (-)CGJ, (2R,3S)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,4- dihydro-2H-l-benzopyran-3-yl 3,4,5-trihydroxybenzoate [i.e.
  • (+)CG (2R,3R)-2-(3,4- dihydroxyphenyl)-5 ,7-dihydroxy-3 ,4-dihydro-2H- 1 -benzopyran-3 -yl 3,4,5- trihydroxybenzoate [i.e. (-)-ECG], (2S,3S)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,4- dihydro-2H- l-benzopyran-3-yl 3,4,5-trihydroxybenzoate [i.e.
  • (+)-ECG (2R,3R ⁇ 5,7- dihydroxy-2-(3,4,5-trihydroxyphenyi)-3,4-dihydro-2H-l-benzopyram-3-yl 3,4,5- Trihydroxybenzoate [i.e. (-)EGCG], (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4- dihydro-2H-l-benzopyran-3-yl 3,4-dihydroxy-5- methoxybenzoate [i.e.
  • the intranasal adminis tration comprises administration to an olfactory mucosa in the upper third of the nasal cavity, or comprises administering to nasal respirator ⁇ ' mucosa.
  • the disorder comprises a neurodegenerative disease (including but not limited to Alzheimer's Disease, Down Syndrome, multiple sclerosis, Fragile X syndrome, and Parkinson disorders), systemic amyloidosis, cancer (including but not limited to glioblastoma, and a congenital hyperinsulinemia (CHI) disorder (including but not limited to Hyperinsulinemia- Hyperammonemia Syndrome (HHS or HI/HA) and short-chain 3-hydroxyacyl-CoA dehydrogenase (SCAD) deficiency).
  • CHI congenital hyperinsulinemia
  • HHS or HI/HA Hyperinsulinemia- Hyperammonemia Syndrome
  • SCAD short-chain 3-hydroxyacyl-CoA dehydrogenase
  • the di sclosure provides methods for treating a congenital hyperinsulinemia (CHI) disorder, comprising administration to a subject in need thereof of an amount effective of (-)EGCG, (-)GCG, (+)-GCG, (-)CG, or a pharmaceutically acceptable salt thereof to treat the disorder in the subject.
  • CHI disorder comprises Hyperinsulinemia-Hyperammonemia Syndrome (HHS or HI/HA) and short-chain 3-hydroxyacyl-CoA dehydrogenase (SCAD) deficiency.
  • the administration comprises oral, intravenous, intranasal, intrapulmonary, intrabronchial, subcutaneous, buccal, sublingual, cutaneous, intradermal, intramuscular administration.
  • the disclosure provides intranasal pharmaceutical formulations comprising a polyphenolic compound and a pharmaceutically acceptable diluent or carrier.
  • a“polyphenolic compound” is a compound characterized by the presence of 2 or more (i.e., 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) phenol structural units.
  • formulations and methods disclosed herein improve overall bioavailability of polyphenolic compounds by administering via the nasal route in order to deliver them through the nasal mucosa and to reduce the dose required for a beneficial effect.
  • polyphenolic compounds exemplified by catechins can be successfully administered by the intranasal route and that the drug is surprisingly more rapidly absorbed following intranasal administration, including in the brain, compared to the corresponding oral dose, leading to a more rapid onset of action and efficacy at lower doses.
  • the polyphenolic compound comprises a compound selected from the group consisting of fiavonoids, curcumin, resveratrol, or pharmaceutically acceptable salts thereof.
  • Curcumin is (lA,6/i)-l,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-l,6-diene- 3,5-dione (CAS 458-37-7).
  • Resveratrol is 3,5,4'-trihydroxy-/rara-stilbene (CAS 501-36-0).
  • Fiavonoids have a general structure of a 15-carbon skeleton, which consists of two phenyl rings (A and B) and heterocyclic ring (C). This carbon structure can be abbreviated C6-C3- C6. They can be classified into:
  • isoflavenoids derived from 3-phenylchromen-4-one (3-phenyl- 1,4- benzopyrone) structure
  • Flavans which include Flavan-3-ols derived from 2-(3,4- dihydroxyphenyl)-3,4-dihydro-2H-l-benzopyran-3,5,7-triol
  • Anthocyamdins derived from 2-phenylchromenylium Theaflavins which contain the 3,4,5-trihydroxy- i,8-bis(3, 5,7- trihydroxy-3,4-diliydro-2H- l-benzopyran-2-yl)-6H-benzo[7]annulen-
  • the phenolic derivative comprises a catechin or a pharmaceutically acceptable salt thereof.
  • a catechin is a flavonoid compound of formula or its derivatives.
  • Green tea and its major constituent polyphenols are also known as green tea catechins (GTCs); Epigallocatechin-3-gallate (EGCG), the major component of GTCs, accounts for approximately 59% of the total polyphenols in dry green tea leaves.
  • GTCs green tea catechins
  • EGCG epigallocatechin
  • EC epigallocatechin
  • EC epicatechin
  • C catechin
  • GCG gallocatechin galiate
  • GCj catechin galiate
  • GCj gallocatechin
  • EGCG and analogs thereof bearing a gallic group in position 3’ can be used for: protection against degenerative diseases;
  • EGCG and analogs thereof bearing a gallic group in position 3 ’ can also be used for the treatment of numerous central and peripheral di sorders including Down
  • DS Alzheimer’s disorders
  • MS Multiple sclerosis
  • PD Parkinson disorders
  • Fragile X syndrome systemic amyloidosis
  • cancer and hyperinsulinemia
  • hyperammonemia syndrome HHS
  • the poor pharmacokinetic properties of EGCG has precluded its therapeutic use other than at very high concentrations that lead to toxic side effects.
  • the intranasal formulations described herein surprisingly provide significantly enhanced access of the active agent to the systemic circulation and to the brain. This permits use of significantly lower doses thereby causing lesser side effect.
  • the formulations can be used for intranasal deli very of all polyphenoiic compounds.
  • the catechin comprises one or more of (2S,3R)-5,7- dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H- Tbenzopyran-3-yl 3,4,5- trihydroxybenzoate j i.e. (-)GCG], (2R,3S)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4- dihydro-2H- l-benzopyran-3-yl 3,4,5 -trihydroxybenzoate [i.e.
  • (+)CG (2R,3R)-2-(3,4- dihydroxyphenyl)-5,7-dihydroxy-3,4-dihydro-2H- 1 -benzopyran-3 -yl 3,4,5- trihydroxybenzoate [i.e. (-)-ECG], (2S,3S)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,4- dihydro-2H ⁇ l -benzopyran-3 -yl 3,4,5-trihydroxybenzoate [i.e.
  • (+)-ECG (2R,3R)5,7- dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-l-benzopyran-3-yl 3,4,5- Trihydroxybenzoate [i.e. (-)EGCG], (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4- dihydro-2H-l -benzopyran-3 -yl 3,4-dihydroxy-5- methoxy benzoate [i.e.
  • the catechin is present in the formulation at between about 1% to about 40% w/w, between about 1% to about 30% w/w, between about 1% to about 25% w/w, between about 4% to about 30% w/w, between about 5% to about 30% w/w, between about 6% to about 30% w/w, between about 8% to about 30% w/w, between about 10% to about 25% w/w, between about 11% to about 25% w7w, or about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12% w/w, 24%, 25%, or 30%.
  • the formulation may further comprise one or more of:
  • the formulation has a pH of between 4.0 and 6.5
  • a pemieation enhancer increases permeability of the poiyphenohc compound through title nasal membrane.
  • a humectant helps increase solubility.
  • An anti-oxidant/chelator helps stabilize the poiyphenohc compound from auto-oxidation.
  • a pH modifier helps make the pH physiological and non-irritating (pH 5.0 - 6.5 for nasal mucosa). These components also help in obtaining ideal osmolarity (i.e. 300 - 700 mOsmol/kg) and increasing the viscosity of the solution as such increasing the residence time and improving absorption.
  • permeation enhancer is present at about 1.0% to about 20%, 1- 18%, 2-18%, 3-17%, 4-16%, 5-15%, 6-14%, 7-13%, 8-12%, 9-1 1%, 2.3-10%, 0.1 % to 2% or about 10% w/w%.
  • Suitable permeation enhancers include HR-b-CD, glycerin, and chitosan, transmucosal delivery enhancement agents including but not limited to alkyisaccharide transmucosal delivery enhancement agents (including but not limited to tetradecyl maltoside (TDM)), or combinations thereof.
  • TDM tetradecyl maltoside
  • the permeation enhancer comprises HR-b-CD (such as at a concentration of from about 1.0% to about 20% w/w or any of the alternative embodiments listed for permeation enhancers in general), chitosan (such as at a concentration of from about 0.1% to about 2% w/w or any of the relevant alternative embodiments listed for permeation enhancers in general), glycerin (such as at a concentration of from about 1 % to about 10% w/w or any of tire relevant alternative embodiments listed for permeation enhancers in general), PEG 300 (such as at a concentration of from about 1% to about 20% w/w or any of the relevant alternative embodiments listed for penneation enhancers in general), PEG 400 (such as at a concentration of from about 1% to about 20% w/w or any of the relevant alternative embodiments listed for permeation enhancers in general), PEG 600 (such as at a concentration of from about 1% to about 20% w/w or any of the relevant alternative embodiments listed for perme
  • penneation enhancers we can increase the solubility of polyphenol derivatives such as catechms in water to more than 10% w/w. This allows a more concentrated solution to be administered facilitating a rapid onset of action and reducing irritancy.
  • One particular formulation comprises catechin, such as GCG, between about 1% and about 30% w/w% or about 10% and about 25% w/w%, or about 10% and about 25% w/w%, or about 1% and about 12% w/w%, m a buffered aqueous solution.
  • the pH of the solution may be adjusted to pH 3-5, or to about pH 4.2 by the addition of a base such as sodium hydroxide.
  • a base such as sodium hydroxide
  • the permeation enhancer comprises one or more compounds selected from the group consisting of cyclodextrin or analogs thereof, glycerin, PEG 400, sucrose inonolaurate, chitosan, transmucosal delivery- enhancement agents including but not limited to alkyisaccharide transmucosal delivery enhancement agents (including but not limited to tetradecyl maltoside (TDM)), or pharmaceutically acceptable salts thereof.
  • TDM tetradecyl maltoside
  • the permeation enhancer comprises one or more compounds selected from the group consisting of (2-Hydroxypropyl)-p-cyciodextrin (HR-b-cyclodextrin); also referred to as HR-b-CD, or Hydroxypropyl betadex), randomly methylated cyclodextrin (also referred to as KM-b-CD), sulfobutylether-P-cyclodextrin (also referred to as SBE-p-CD), sucrose monolaurate, pharmaceutically acceptable salts thereof, or combinations thereof.
  • HR-b-cyclodextrin also referred to as HR-b-CD, or Hydroxypropyl betadex
  • KM-b-CD randomly methylated cyclodextrin
  • SBE-p-CD sulfobutylether-P-cyclodextrin
  • sucrose monolaurate pharmaceutically acceptable salts thereof, or combinations thereof.
  • the anti-oxidant/chelators is present at 0.05-15%, 0.8-15%, 0.1-15%, 0.1-10%, 0.1-9%, 0.1-6%, or about 0.2%, 1%. 2%, 3%, 4%, 5% w/w%.
  • Additional stabilizers may be used to improve chemical stability of tire formulations; i.e. anti-oxidants such as ascorbic acid, sodium metabisulfite, sodium bisulfite or tocopherol, or metal chelators such as ethyienedaminetetraacetic acid (EDTA).
  • anti-oxidants such as ascorbic acid, sodium metabisulfite, sodium bisulfite or tocopherol
  • metal chelators such as ethyienedaminetetraacetic acid (EDTA).
  • the anti-oxidant comprises one or more compounds selected from the group consisting of ascorbic acid, sodium metabisulfite, sodium bisulfite, tocopherol, or pharmaceutically acceptable salts thereof. In another embodiment, the anti-oxidant comprises ascorbic acid or a pharmaceutically acceptable salt thereof.
  • humectants may also be added to improve the patient acceptability of the formulations.
  • the humeetant may be present at 1- 25%, 1-20%, 1-15%, 1-10%, 1-9%, 2-8%, 3-7%, 4-6%, or about 5% w/w%.
  • the humeetant comprises a compound selected from the group consisting of glycerin, PEG (including but not limited to PEG 300, PEG400, and PEG 600), or a pharmaceutically acceptable salt thereof
  • the formulations may be buffered to pH 3-8, more preferably 4 to 7 using buffer systems, such as citrate, lactate, sodium hydroxide, or phosphate buffers to control the pH.
  • buffer systems such as citrate, lactate, sodium hydroxide, or phosphate buffers to control the pH.
  • osmo!arity may be adjusted so that the formulation is isotonic using standard osmogens (e.g. sodium chloride, mannitol or glucose).
  • the formulation comprises a pH modifier present at 0.1-2%, 0.5-1.5% or about 1% w/w%.
  • the pH modifier comprises a compound selected from the group consisting of sodium hydroxide or a pharmaceutically acceptable salt thereof.
  • the intranasal pharmaceutical formulation may comprise any suitable form for intranasal administration ln various embodiments, the formulation may comprise a liquid, a powder, a spray, a nose drop, a gel, an ointment, or a combination thereof.
  • composition can be formulated, for example, as a nasal emulsion, ointment, gel, (which offer advantages for local application because of their viscosity) or can be, for example powder formulations or nasal sprays.
  • Such sprays typically comprise a solution of the active drug in physiological saline or other pharmaceutically suitable carrier liquids.
  • Various nasal spray compression pumps can be used and calibrated to deliver a
  • the nasal formulations may be capable of delivering a poiyphenolie compound dose (such as catechins) between about 1 mg to about 100 mg, or between about 5 mg to 20 mgs per shot (i.e.: per pump of a nasal spray) which can be given as one or more shots per nostril.
  • a poiyphenolie compound dose such as catechins
  • a poiyphenolie compound dose between about 1 mg to about 100 mg, or between about 5 mg to 20 mgs per shot (i.e.: per pump of a nasal spray) which can be given as one or more shots per nostril.
  • intranasal solution formulations typically volumes used to deliver between about 1 rng to about 100 mg, or between about 5 mg to 20 mgs man are 25 to 200 pL, or 75 to 150 pL per dose in each nostril.
  • the intranasal solution formulations can be administered as drops from a nasal dropper bottle or as aerosols after being applied from squeeze bottles, single unit dose or metered-dose pump sprays.
  • Idle dose of poiyphenolie compound such as a catechin can be combined with a mucoadhesive to enhance its contact with the olfactory mucosa.
  • the mucoadhesive is selected from the group consisting of a hydrophilic polymer, a hydrogel and a thermoplastic polymer.
  • Preferred hydrophilic polymers include cellulose-based polymers (such as methylce!lulose, hydroxyethyl cellulose, hydroxy propyl methyl cellulose, sodium carboxy methyl cellulose), a carbomer chitosan and plant gum.
  • the mucoadhesive is selected from the group consisting of poly(lactic acid) (“PLA”) and po!y(glycolic acid) (“PGA”), and copolymers thereof.
  • the mucoadhesive formulation includes a penetration enhancer such as sodium g!yeocholate, sodium taurocholate, L-lysophosphotidy! choline, DMSO and a protease inhibitor.
  • the pharmaceutical composition includes a pharmaceutically acceptable carrier, a lipophilic micelle, a liposome, or a combination thereof.
  • the lipophilic micelle or liposome may comprise a ganglioside, a phosphatidylcholine, a
  • phosphatidylserine or a combination thereof.
  • intranasal delivery it can be desirable to prolong the residence time of the pharmaceutical composition in the nasal cavity (e.g , in the olfactory region and/or in the sinus region), for example, to enhance absorption.
  • the pharmaceutical composition in the nasal cavity (e.g , in the olfactory region and/or in the sinus region), for example, to enhance absorption.
  • composition can optionally be formulated with a bioadhesive polymer, a gum (e.g., xanthan gum), chitosan (e.g., highly purified cationic polysaccharide), pectin (or any carbohydrate that thickens like a gel or emulsifies when applied to nasal mucosa), a microsphere (e.g., starch, albumin, dextran, cyclodextrin), gelatin, a liposome, carbamer, polyvinyl alcohol, alginate, acacia, chitosans and/or cellulose (e.g., methyl or propyl: hydroxyl or carboxy; carboxymethyl or hydroxylpropyl), which are agents that enhance residence time in the nasal cavity.
  • a bioadhesive polymer e.g., xanthan gum
  • chitosan e.g., highly purified cationic polysaccharide
  • pectin or any
  • the pharmaceutical formulation can also optionally include an absorption enhancer, such as an agent that inhibits enzyme activity, reduces mucous viscosity or elasticity, decreases mucociliary clearance effects, opens tight junctions, and/or solubilizes the active compound.
  • an absorption enhancer such as an agent that inhibits enzyme activity, reduces mucous viscosity or elasticity, decreases mucociliary clearance effects, opens tight junctions, and/or solubilizes the active compound.
  • Chemical enhancers are known in the art and include chelating agents (e.g., EDTA), fatty acids, bile acid salts, surfactants, and/or preservatives. Enhancers for penetration can he particularly useful when formulating compounds that exhibit poor membrane permeability, lack of lipophilicity, and/or are degraded by aminopeptidases.
  • the concentration of the absorption enhancer in the pharmaceutical composition will vary depending upon the agent selected and the formulation.
  • preservatives can optionally be added to the pharmaceutical formulation.
  • Suitable preservatives include but are not limited to benzyl alcohol, parabens, thimerosal, chlorobutanol and benzalkoniurn chloride, and combinations of tire foregoing.
  • the concentration of the preservative will van ' depending upon the preservative used, the compound being formulated, the formulation, and the like.
  • the preservative is present in an amount of 2%, 1%, 0.5%, 0.2%, 0.1%, 0.03%, by weight or less (or not present at all).
  • the pharmaceutical formulation can optionally contain an odorant to provide a sensation of odor, to aid in inhalation of the composition so as to promote delivery ' to the olfactory epithelium and/or to trigger transport by the olfactory neurons.
  • the pharmaceutical formulations may also optionally include a thickener, which may be present in an amount of 1 %, 0.5%, 0.2%, 0.1 % by weight or less (or not present at all).
  • Single unit-dose spray can be prepared aseptically or terminally sterilized to produce a sterile final product.
  • effecti ve concentrations of one or more compounds or pharmaceutically acceptable derivatives is (are) mixed with a suitable pharmaceutical carrier or vehicle.
  • the compounds may be derivatized as the corresponding salts, esters, enol ethers or esters, acids, bases, solvates, hydrates or prodrugs prior to formulation.
  • Any suitable carrier or di luent may be used, including but not limited to a sol vent of di spersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
  • the disclosure provides method for treating a central nervous system disorder, a congenital hyperinsulinemia (CHI) disorder, a tumor, diabetes, obesity, or a systemic disorder, comprising intranasal administration to a subject in need thereof of an amount effective of a polyphenolic compound (such as a catechin) or a pharmaceutically acceptable salt thereof to treat the disorder in the subject, or by administering an intranasal pharmaceutical formulation of any embodiment of the disclosure, to treat the disorder in the subject.
  • a polyphenolic compound such as a catechin
  • an intranasal pharmaceutical formulation of any embodiment of the disclosure to treat the disorder in the subject.
  • polyphenolic compounds exemplified by catechins can be successfully administered by the intranasal route and that the drug is surprisingly more rapidly absorbed following intranasal administration, including in the brain, compared to the corresponding oral dose, leading to a more rapid onset of action and efficacy at lower doses.
  • the methods disclosed herein provide significant benefits over previous methods for using catechins to treat such disorders.
  • polyphenol derivati ves such as catechins
  • the present inventor noted that there are many bioavailability problems associated with the oral delivery of catechins especially into the brain.
  • the formulations disclosed herein significantly increase exposure in the brain and allow the use of significantly lower therapeutic doses as such increasing the overall safety and significantly reducing toxicity- . Increasing bioavailability of the drag using the formulations disclosed herein will also be beneficial for indications outside the CNS.
  • the polyphenolic compound may- comprise one or more of (2S,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H- l-benzopyran-3-yl 3,4,5- trihydroxybenzoate [i.e. (-)GCG], (2R,3S)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4- dihydro-2H-l-benzopyran-3-yl 3,4,5-trihydroxybenzoate [i.e.
  • (+)GCG (2S,3R)-2-(3,4- dihy droxyphenyl)-5 ,7 -dihydroxy-3 ,4-dihydro-2H- 1 -benzopyran-3 -yl 3 ,4,5 - trihydroxybenzoate [i.e. (-)CGj, (2R,3S)-2-(3 ,4-dihydroxyphenyl)-5, 7-dihydrox -3,4- dihydro-2H-l -benzopyran-3 -yd 3,4,5-trihydroxybenzoate [i.e.
  • (+)GG (2R perennial caretake3R) ⁇ 2-(3,4- dihydroxyphenyi) ⁇ 5 ,7-dihydroxy-3 ,4-dihydro ⁇ 2H ⁇ 1 -benzopyran-3 -yl 3,4,5- trihydroxybenzoate [i.e. (-)-ECG], (2S,3S)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,4- dihydro-2H-l -benzopyran-3 -yl 3,4,5-trihydroxybenzoate [i.e.
  • (+ ⁇ ECG] (2R,3R)5,7- dihydroxy-2-(3, 4, 5-trihydroxyphenyl)-3, 4-dihydro- 2H-l-benzopyran-3-yl 3,4,5- Trihydroxybenzoate [i.e. (-)EGCGj, (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4- dihydro-2H- l-benzopyran-3-yl 3,4-dihydroxy-5- methoxybenzoate [i.e.
  • the method of the present disclosure includes applying the pharmaceutical composition to an olfactory area in the upper third of the nasal cavity, such as the olfactory mucosa. In some embodiments, the method of the present invention includes applying the pharmaceutical composition to the nasal respiratory mucosa in order to deliver drug systemically.
  • the disorder comprises a neurodegenerative disease, including but not limited to Alzheimer's Disease, Down Syndrome, multiple sclerosis, and Parkinson disorders.
  • the disorder is selected from the group consisting of systemic amyloidosis, Fragile X, and cancer.
  • the cancer comprises glioblastoma.
  • the disorder comprises a congenital hyperinsulinemia (CHI) disorder.
  • Congenital hyperinsulinemia is a medical temi referring to a variety of congenital disorders in which hypoglycemia is caused by excessive insulin secretion. Congenital forms of hyperinsulinemia hypoglycemia can be transient or persistent, mild or severe. HHS is a rare autosomal dominant disease manifested by hypoglycemic symptoms triggered by fasting or high-protein meals, and by elevated serum ammonia. It is the second most common cause of hyperinsulinemic hypoglycemia m infancy.
  • GDH glutamate dehydrogenase
  • HHS has profound effects on several major organs.
  • dysregulated GDH causes an exaggerated insulin response to amino acid consumption, leading to hypoglycemia.
  • glutamate catabolism decreases urea synthesis by
  • CNS carbamoylphosphate synthetase
  • Inhibitors of GDH can also be very useful for the treatment of another congenital hyperinsulinemia disorder associated with inactivating mutations of short-chain 3-hydroxyacyl-CoA dehydrogenase (SCHAD). It is caused by a mutation in the HADH gene (4q22-q26) encoding the SCHAD protein that has a dual function both as an enzyme and an inhibitor of GDH. It is an ultra-rare genetic disease whose prevalence is estimated at ⁇ 1 in 1,000,000 new born/yr).
  • SCHAD short-chain 3-hydroxyacyl-CoA dehydrogenase
  • GDH Glutamate Dehydrogenase
  • the CHI disorder comprises Hyperins ulinemia-Hyperammonemia Syndrome (HHS or HI/HA) and short-chain 3 -hydroxy acyl-CoA dehydrogenase (SCAD) deficiency.
  • HHS or HI/HA Hyperins ulinemia-Hyperammonemia Syndrome
  • SCAD short-chain 3 -hydroxy acyl-CoA dehydrogenase
  • the disclosure provides methods for treating a congenital hyperinsuiinemia (CHI) disorder, comprising administration to a subject in need thereof of an amount effective of (-)EGCG, (-)GCG, (+)-GCG, (-)CG, or a pharmaceutically acceptable salt thereof to treat the disorder in the subject.
  • CHI congenital hyperinsuiinemia
  • the inventor show's in the examples that follow below that (-)GCG, (+)-GCG, (-)CG are significantly better GDH inhibitors that
  • the CHI disorder comprises Hyperinsulinemia-Hyperamnionemia Syndrome (HHS or HI/HA) and short-chain 3-hydroxyacyl-CoA dehydrogenase (SCAD) deficiency.
  • HHS or HI/HA Hyperinsulinemia-Hyperamnionemia Syndrome
  • SCAD short-chain 3-hydroxyacyl-CoA dehydrogenase
  • the administration comprises oral, intravenous, intranasal, intrapulrnonary, intrabronchial, subcutaneous, buccal, sublingual, cutaneous, intradermal, intramuscular administration.
  • the subject may be any suitable subject that might benefit from treatment, including any mammal that might benefit.
  • the subject is a human subject.
  • "treat” or “treating” means accomplishing one or more of tire following: (a) reducing the severity of the disorder; (b) limiting or preventing development of symptoms characteristic of the disorders) being treated; (c) inhibiting worsening of symptoms characteristic of the disorders) being heated; (d) limiting or preventing recurrence of the disorders) in patients that have previously had the disorders); and (e) limiting or preventing recurrence of symptoms in patients that were previously symptomatic for the disorder) s).
  • the catechins and formulations can be administered as tire sole active pharmaceutical agent, or they can he used in combination with one or more other compounds useful for carrying out the methods of the invention.
  • tire therapeutic agents can be formulated as separate compositions that are given at the same time or different times, or the therapeutic agents can be given as a single composition.
  • compositions are administered in an amount sufficient to ca ' out the methods of the disclosure.
  • Amounts effective for these uses depend on factors including, but not limited to, the nature of the compound (specific activity, etc.), the route of administration, the stage and severity of the disorder, the weight and general state of health of the subject, and the judgment of the prescribing physician.
  • the active compounds are effective over a wide dosage range, such as those disclosed herein. However, it will be understood that the amount of the compound actually administered will be determined by a physician, in the light of the above relevant circumstances. Therefore, the above dosage ranges are not intended to limit the scope of the invention in any way.
  • the composition may also be added to the animal teed or drinking water. It may be convenient to formulate these animal feed and drinking water compositions so that the animal ingests an appropriate quantity of the composition during a meal or throughout the course of the day. It may also be convenient to present the composition as a premix for addition to the feed or drinking water.
  • composition :
  • Formulation composition follows table above for total test article amount of 100 am. to be performed at room temperature (RT) Adjustments to total preparation amount may be scaled appropriately meeting composition stated in the Table above
  • Step 1 Add 60 gm of Purified Water, USP to a 250 inL glass beaker containing a magnetic stir bar. Place the glass beaker on a stirring plate and stir the Purified Water, USP at approximately 250 revolutions per minute (RPM).
  • RPM revolutions per minute
  • Step 2 To Step 1 preparation, add 5 gm of Ascorbic Acid, USP in small increments and allow to dissolve.
  • Step 3 To Step 2 preparation, add 1 gm of Sodium Hydroxide, NF, USP in small increments and allow to dissolve.
  • Step 4 To Step 3 preparation, add 10 gm of HP-p-cyclodextrin in small increments and allow to hydrate and dissolve. This step may take a few' minutes since it consists in the dissolution of the polymer.
  • Step 5 To Step 4 preparation, add 5 gm of Glycerin, USP and mix properly to ensure a solution preparation.
  • Step 6 To Step 5 preparation, add (-)-EGCG in small increments and allow to dissolve.
  • Step 7 To Step 6 preparation, Q.S. (dilute to weight) to total formulation amount of 100 gm. Using a pH meter (previously calibrated at 4.0 and 7.0 buffer solution) or pH indicator strips for 4.0 - 7.0, verify that final pH of the formulation in Step 6 is approximately 5.5 (range 5.0 - 6.0). Allow solution to continuously mix before vivo dosing.
  • Intranasal solution formulation for (-)-GCG was prepared of the following composition
  • Formulation composition follows table above for total test article amount of 100 gm. to be performed at room temperature (RT). Adjustments to total preparation amount may be scaled appropriately meeting composition stated in the Table above.
  • Step 1. Add 60 gm of Purified Water, USP to a 250 rnL glass beaker containing a magnetic stir bar. Place the glass beaker on a stirring plate and stir the Purified Water, USP at approximately 250 revolutions per minute (RPM).
  • RPM revolutions per minute
  • Step 2 To Step 1 preparation, add 5 gm of Ascorbic Acid, USP in small increments and allow to dissolve.
  • Step 3 To Step 2 preparation, add 1 gm of Sodium Hydroxide, NF, USP in small increments and allow to dissolve.
  • Step 4 To Step 3 preparation, add 10 gm of HR-b-cyclodextrin in small increments and allow to hydrate and dissolve. This step may take a few' minutes since it consists in the dissolution of the polymer.
  • Step 5 To Step 4 preparation, add 5 gm of Glycerin, USP and mix properly to ensure a solution preparation.
  • Step 6 To Step 5 preparation, add (-)-GCG in small increments and allow to dissolve.
  • Step 7 To Step 6 preparation, Q.S. (dilute to weight) to total formulation amount of 100 gm. Using a pH meter (previously calibrated at 4.0 and 7.0 buffer solution) or pH indicator strips for 4.0 - 7.0, verify that final pH of tire formulation in Step 6 is approximately 5.5 (range 5.0 - 6.0). Allow solution to continuously mix before in vivo dosing.
  • Intranasal solution formulation for (-)-CG was prepared of the following composition:
  • Formulation composition follows table above for total test article amount of 100 gm. to be performed at room temperature (RT). Adjustments to total preparation amount may be scaled appropriately meeting composition stated in the Table above Step 1 Add 60 gm of Purified Water, USP to a 250 inL glass beaker containing a magnetic stir bar. Place the glass beaker on a stirring plate and stir the Purified Water, USP at approximately 250 revolutions per minute (RPM).
  • RPM revolutions per minute
  • Step 2 To Step 1 preparation, add 5 gm of Ascorbic Acid, USP in small increments and allow to dissolve.
  • Step 3 To Step 2 preparation, add 1 gm of Sodium Hydroxide, NF, USP in small increments and allow to dissolve.
  • Step 4 To Step 3 preparation, add 10 gm of HR-b-cyclodextrin in small increments and allow to hydrate and dissolve. This step may take a few' minutes since it consists in the dissolution of the polymer.
  • Step 5 To Step 4 preparation, add 5 gm of Glycerin, USP and mix properly to ensure a solution preparation.
  • Step 6 To Step 5 preparation, add (-)-CG in small increments and allow' to dissolve.
  • Step 7 To Step 6 preparation, Q.S. (dilute to weight) to total formulation amount of 100 gm. Using a pH meter (previously calibrated at 4.0 and 7.0 buffer solution) or pH indicator strips for 4.0 - 7.0, verify that final pH of tire formulation in Step 6 is approximately 5.5 (range 5.0 - 6.0). Allow ' solution to continuously mix before in vivo dosing.
  • Intranasal solution formulation for (-)-GCG was prepared of the following
  • composition :
  • Formulation composition follows table above for total test article amount of 100 gm. to be performed at room temperature (RT). Adjustments to total preparation amount may be scaled appropriately meeting composition stated in the Table above.
  • Step 1 Add 60 gm of Purified Water, USP to a 250 mL glass beaker containing a magnetic stir bar. Place the glass beaker on a stirring plate and stir the Purified Water, USP at approximately 250 revolutions per minute (RPM).
  • RPM revolutions per minute
  • Step 2 To Step 1 preparation, add 10 gm of PEG400 in small increments and allow to dissolve.
  • Step 3 To Step 2 preparation, add 0.2 gm of EDTA in small increments and allow to dissolve.
  • Step 4 To Step 3 preparation, add 0.03gm or benzyl alcohol
  • Step 5 To Step 4 preparation, add 10 gm of HR-b-cyclodextrin in small increments and allow to hydrate and dissolve. This step may take a few minutes since it consists in the dissolution of the polymer.
  • Step 6 To Step 5 preparation, add 10 gm of (-)-GCG in small increments and allow to dissolve.
  • Step 7 To Step 6 preparation, Q.S. (dilute to weight) to total formulation amount of 100 gm.
  • Intranasal solution formulation for (-)-GCG was prepared of the following
  • composition :
  • Formulation composition follows table above for total test article amount of 100 gm. to be performed at room temperature (RT). Adjustments to total preparation amount may be scaled appropriately meeting composition stated in the Table above.
  • Step 1 Add 60 gm of Purified Water, USP to a 250 mL glass beaker containing a magnetic stir bar. Place the glass beaker on a stirring plate and stir the Purified Water, USP at approximately 250 revolutions per minute (RPM).
  • RPM revolutions per minute
  • Step 2 To Step 1 preparation, add 11 gm of PEG400
  • Step 3 To Step 2 preparation, add 0.08 gm of EDTA and allow to dissolve.
  • Step 4 To Step 3 preparation, add 0.1 gm of sucrose monolaurate
  • Step 5 To Step 4 preparation, add 2.2 gm of HR-b-cyclodextrin
  • Step 6 To Step 5 preparation, add 11 gm of (-)-GCG in small increments and allow to dissolve.
  • Step 7 To Step 6 preparation, Q.S. (dilute to weight) to total formulation amount of
  • Intranasal solution formulation for (-)-GCG was prepared of the following composition
  • Formulation composition follows table above for total test article amount of 100 gm. to be performed at room temperature (RT). Adjustments to total preparation amount may be scaled appropriately meeting composition stated in the Table above.
  • Step 1 Add 60 gm of Purified Water, USP to a 250 mL glass beaker containing a magnetic stir bar. Place the glass beaker on a stirring plate and stir the Purified Water, USP at approximately 250 revolutions per minute (RPM).
  • RPM revolutions per minute
  • Step 2 To Step 1 preparation, add 10 gm of PEG400
  • Step 3 To Step 2 preparation, add 0.2 gm of EDTA and allow to dissolve.
  • Step 4 To Step 3 preparation, add Q.G3g of benzyl alcohol
  • Step 5 To Step 4 preparation, add dlO gm of Methyi-p-cyclodextrin
  • Step 6 To Step 5 preparation, add 1 gm of (-)-GCG in small increments and allow to dissolve.
  • Step 7 To Step 6 preparation, Q.S. (dilute to weight) to total formulation amount of 100 gm.
  • Intranasal solution formulation for (-)-GCG was prepared of the following composition:
  • Formulation composition follows table above for total test article amount of 100 gm. to be performed at room temperature (RT). Adjustments to total preparation amount may be scaled appropriately meeting composition stated in the Table above.
  • Step 1 Add 60 gm of Purified Water, USP to a 250 mL glass beaker containing a magnetic stir bar. Place the glass beaker on a stirring plate and stir the Purified Water, USP at approximately 250 re volutions per minute (RPM).
  • RPM re volutions per minute
  • Step 2 To Step 1 preparation, add 10 gm of PEG400
  • Step 3 To Step 2 preparation, add 0.2 gm of EDTA and allow to dissolve.
  • Step 4 To Step 3 preparation, add 0.03g of benzyl alcohol
  • Step 5 To Step 4 preparation, add dlO gm of HR-b-cyclodextrin
  • Step 6 to Step 5 add 0.1 g of Hydroxypropyl methyl cellulose (HPMC)
  • Step 7 To Step 6 preparation, add 1 gm of (-)-GCG in small increments and allow to dissolve.
  • Step 8 To Step 7 preparation, Q.S. (dilute to weight) to total formulation amount of
  • the bovine GDH (bGDH) used for these assays was obtained from Sigma Aldrich Chemical Co as a concentrated stock solution preserved with 50% glycerol. GDH was diluted to a final concentration of 0.01 mg/mL in 0.1 M sodium phosphate buffer, pH 8.0.
  • the substrate mix consisted of 2.0 mM NAD and 200 mM sodium glutamate in 0.1 M sodium phosphate buffer, pH 8.0.
  • the stop solution for this reaction was 0.8% sodium dodecyl sulfate in water.
  • Test compound is dissolved in DMSO and added to the cuvete. The enzyme solution was added followed by the addition of the substrate solution. Hie resulting solution is quickly mixed and NADH production is monitored at 340 nm wavelength.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des formulations pharmaceutiques intranasales comprenant un composé polyphénolique et un diluant ou un support pharmaceutiquement acceptable, et des procédés pour leur utilisation dans le traitement de troubles du système nerveux central, d'un trouble d'hyperinsulinémie congénitale, de tumeurs ou de troubles systémiques.
PCT/US2019/035302 2018-06-07 2019-06-04 Procédés et formulations pour une administration intranasale WO2019236521A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862682055P 2018-06-07 2018-06-07
US62/682,055 2018-06-07

Publications (1)

Publication Number Publication Date
WO2019236521A1 true WO2019236521A1 (fr) 2019-12-12

Family

ID=67185699

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/035302 WO2019236521A1 (fr) 2018-06-07 2019-06-04 Procédés et formulations pour une administration intranasale

Country Status (1)

Country Link
WO (1) WO2019236521A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113975223A (zh) * 2021-08-06 2022-01-28 华中科技大学 一种鼻腔清洗液

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002072086A2 (fr) * 2001-03-12 2002-09-19 Consorzio Per Gli Studi Universitari Utilisation de l'epigallocatechin-3-gallate ou des derives de celui-ci dans la prevention et le traitement de maladies neurodegeneratives
WO2003086429A1 (fr) * 2002-04-16 2003-10-23 Medestea Research & Production S.R.L. Formulation pharmaceutique pour administration endonasale et son utilisation dans le traitement de symptomes rhinitiques
US20060189542A1 (en) * 2003-07-22 2006-08-24 Satoru Furukawa Preventive or therapeutic composition for viral infectious disease
US20080075671A1 (en) * 2006-09-22 2008-03-27 Di Mauro Thomas M Intranasally administering curcumin to the brain to treat alzheimer's disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002072086A2 (fr) * 2001-03-12 2002-09-19 Consorzio Per Gli Studi Universitari Utilisation de l'epigallocatechin-3-gallate ou des derives de celui-ci dans la prevention et le traitement de maladies neurodegeneratives
WO2003086429A1 (fr) * 2002-04-16 2003-10-23 Medestea Research & Production S.R.L. Formulation pharmaceutique pour administration endonasale et son utilisation dans le traitement de symptomes rhinitiques
US20060189542A1 (en) * 2003-07-22 2006-08-24 Satoru Furukawa Preventive or therapeutic composition for viral infectious disease
US20080075671A1 (en) * 2006-09-22 2008-03-27 Di Mauro Thomas M Intranasally administering curcumin to the brain to treat alzheimer's disease

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BAHI-BUISSON N.E. ROZEC. DIONISIF. ESCANDEV. VALAYANNOPOULOSF. FEILLETC. HEINRICHS, DEV. MED. & CHILD NEURAL., vol. 50, 2008, pages 945 - 949
CHANGHONG LI ET AL: "Green Tea Polyphenols Modulate Insulin Secretion by Inhibiting Glutamate Dehydrogenase", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 281, no. 15, 13 February 2006 (2006-02-13), US, pages 10214 - 10221, XP055615062, ISSN: 0021-9258, DOI: 10.1074/jbc.M512792200 *
CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 501-36-0
H , B.Y.A. KELLYF.S. THORNTONC.R. GREENBERGL.A. DILLINGC.A. STANLEY, J PEDIATR., vol. 138, no. 3, 2001, pages 383 - 389
HO SIYIN ET AL: "Inclusion complexation of catechin by [beta]-cyclodextrins: Characterization and storage stability", LWT- FOOD SCIENCE AND TECHNOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 86, 17 August 2017 (2017-08-17), pages 555 - 565, XP085185623, ISSN: 0023-6438, DOI: 10.1016/J.LWT.2017.08.041 *
LI CALLEN AKWAGH JDOLIBA N MQIN WNAJAFI HCOLLINS HMATSCHINSKY FSTANLEY CASMITH TJ, J BIOL. CHEM., vol. 281, no. 15, 2006, pages 10214 - 10221
NASR: "Development of an optimized hyaluronic acid based lipidic nanoemulsion co-encapsulating two polyphenols for nose to brain delivery", DRUG DELIVERY, vol. 23, no. 4, 24 September 2015 (2015-09-24), pages 1444 - 1452, XP055620448 *
PETERS C M ET AL: "Formulation with ascorbic acid and sucrose modulates catechin bioavailability from green tea", FOOD RESEARCH INTERNATIONAL, ELSEVIER, AMSTERDAM, NL, vol. 43, no. 1, 1 January 2010 (2010-01-01), pages 95 - 102, XP026813703, ISSN: 0963-9969, [retrieved on 20090829] *
STANLEY, C.A.Y.K. LIENB.Y. HSUA.B. BURLINAC.R. GREENBERGN.J. HOPWOODK PERLMANB.H. RICHE. ZAMMARCHIM. PONCZ, NEW ENGLAND JOURNAL OF MEDICINE, vol. 1238, 1998, pages 1352 - 1357
WAGER, TTHOU, XVER OES . PRVILLALOBOS. A, ACS CHEM. NEUROSCI., vol. 1, no. 6, 2010, pages 435 - 449

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113975223A (zh) * 2021-08-06 2022-01-28 华中科技大学 一种鼻腔清洗液

Similar Documents

Publication Publication Date Title
EP1071419B1 (fr) Cannabinoides comme antioxydants et neuroprotecteurs
JP3350061B2 (ja) エレトリプタンヘミスルフェートおよびカフェインを含有する医薬組成物
US20080075671A1 (en) Intranasally administering curcumin to the brain to treat alzheimer's disease
EA008005B1 (ru) Интраназальный препарат ротиготина
EP2723320B1 (fr) Composition pharmaceutique liquide comprenant de la nitisinone
EP1037628A1 (fr) Methodes de prevention de la restenose utilisant des tocotrienols
KR20140021587A (ko) 전립선암 또는 유방암의 치료를 위한 디에틸스틸베스트롤의 투여 형태 및 용도
EP2714024B1 (fr) Formulations orales d'antioxydants ciblés sur les mitochondries et leur préparation et leur utilisation
WO2013036830A1 (fr) Formulations topiques d'itraconazole et leurs utilisations
Xiong et al. Solanesol derived therapeutic carriers for anticancer drug delivery
WO2019236521A1 (fr) Procédés et formulations pour une administration intranasale
AU2012261854A1 (en) Oral formulations of mitochondrially-targeted antioxidants and their preparation and use
WO2002051380A1 (fr) Nouvelle composition pharmaceutique de principes actifs solubles dans l'eau ou peu solubles dans l'eau
Rad et al. Metformin loaded cholesterol-lysine conjugate nanoparticles: a novel approach for protecting HDFs against UVB-induced senescence
EP2735305A1 (fr) Préparations pharmaceutiques liquides stabilisées
US20110293537A1 (en) formulations with anti-neoplastic activity
US20060194800A1 (en) Pteridine derivatives as nitric oxide synthase activators
WO2000038670A1 (fr) Metabolites du propanolol utiles pour leur activite oxydante
AU2006289752B2 (en) Combination drug containing probucol and a tetrazolylalkoxy-dihydrocarbostyril derivative with superoxide supressant effects
JPH11507359A (ja) 安定化ステロイド組成物
US20190160084A1 (en) Methods for the treatment of cancer using meglumine
CA3178819A1 (fr) Compositions cannabinoides et formes posologiques pour administration intranasale ou par inhalation
WO2002002091A2 (fr) Methodes et compositions de traitement de l'alcoolisme et de la dependance a l'alcool
El-Marasy et al. Anti-depressant effect of Naringenin-loaded hybridized nanoparticles in diabetic rats via PPARγ/NLRP3 pathway
KR100384346B1 (ko) 엘레트립탄 헤미술페이트 및 카페인을 포함하는 약제학적조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19736848

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19736848

Country of ref document: EP

Kind code of ref document: A1